Kelly Scaggs Campen
Examiner (ID: 2758, Phone: (571)272-6740 , Office: P/3691 )
Most Active Art Unit | 3691 |
Art Unit(s) | 3624, 2165, 2164, 3312, 3738, 3691 |
Total Applications | 1052 |
Issued Applications | 501 |
Pending Applications | 228 |
Abandoned Applications | 322 |
Applications
Application number | Title of the application | Filing Date | Status |
---|---|---|---|
Array
(
[id] => 17938433
[patent_doc_number] => 11472874
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-10-18
[patent_title] => Anti-MS4A4A antibodies and methods of use thereof
[patent_app_type] => utility
[patent_app_number] => 16/965676
[patent_app_country] => US
[patent_app_date] => 2019-01-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 25
[patent_figures_cnt] => 32
[patent_no_of_words] => 68530
[patent_no_of_claims] => 29
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 106
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16965676
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/965676 | Anti-MS4A4A antibodies and methods of use thereof | Jan 30, 2019 | Issued |
Array
(
[id] => 16871524
[patent_doc_number] => 20210164991
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-06-03
[patent_title] => INDUCED COMMON ANTIBODY RESPONSE
[patent_app_type] => utility
[patent_app_number] => 16/954187
[patent_app_country] => US
[patent_app_date] => 2019-01-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16910
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16954187
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/954187 | INDUCED COMMON ANTIBODY RESPONSE | Jan 15, 2019 | Pending |
Array
(
[id] => 14309653
[patent_doc_number] => 20190144530
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-05-16
[patent_title] => TREATMENT OF ALZHEIMER'S DISEASE SUBPOPULATIONS WITH POOLED IMMUNOGLOBULIN G
[patent_app_type] => utility
[patent_app_number] => 16/247141
[patent_app_country] => US
[patent_app_date] => 2019-01-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 21577
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16247141
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/247141 | TREATMENT OF ALZHEIMER'S DISEASE SUBPOPULATIONS WITH POOLED IMMUNOGLOBULIN G | Jan 13, 2019 | Abandoned |
Array
(
[id] => 14566955
[patent_doc_number] => 20190211084
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-07-11
[patent_title] => ANTI-COMPLEMENT FACTOR C1Q ANTIBODIES AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 16/239685
[patent_app_country] => US
[patent_app_date] => 2019-01-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 35376
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16239685
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/239685 | Anti-complement factor C1q antibodies and uses thereof | Jan 3, 2019 | Issued |
Array
(
[id] => 17859811
[patent_doc_number] => 11440957
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-09-13
[patent_title] => Anti-TMEM106B antibodies and methods of use thereof
[patent_app_type] => utility
[patent_app_number] => 16/959081
[patent_app_country] => US
[patent_app_date] => 2018-12-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 2
[patent_figures_cnt] => 2
[patent_no_of_words] => 55405
[patent_no_of_claims] => 43
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 638
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16959081
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/959081 | Anti-TMEM106B antibodies and methods of use thereof | Dec 20, 2018 | Issued |
Array
(
[id] => 16711928
[patent_doc_number] => 20210079075
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-03-18
[patent_title] => NOVEL MEANS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES
[patent_app_type] => utility
[patent_app_number] => 16/956255
[patent_app_country] => US
[patent_app_date] => 2018-12-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 29304
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16956255
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/956255 | NOVEL MEANS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES | Dec 19, 2018 | Pending |
Array
(
[id] => 17756254
[patent_doc_number] => 11396538
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-07-26
[patent_title] => Antibodies to centrin-1, methods of making, and uses thereof
[patent_app_type] => utility
[patent_app_number] => 16/955751
[patent_app_country] => US
[patent_app_date] => 2018-12-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 19
[patent_figures_cnt] => 18
[patent_no_of_words] => 25505
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 781
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16955751
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/955751 | Antibodies to centrin-1, methods of making, and uses thereof | Dec 19, 2018 | Issued |
Array
(
[id] => 16400136
[patent_doc_number] => 20200340994
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-10-29
[patent_title] => Tumstatin Assay
[patent_app_type] => utility
[patent_app_number] => 16/956369
[patent_app_country] => US
[patent_app_date] => 2018-12-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5938
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 16
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16956369
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/956369 | Tumstatin Assay | Dec 18, 2018 | Abandoned |
Array
(
[id] => 14338873
[patent_doc_number] => 20190151409
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-05-23
[patent_title] => TREATMENT OF AMD USING AAV2 VARIANT WITH AFLIBERCEPT
[patent_app_type] => utility
[patent_app_number] => 16/218353
[patent_app_country] => US
[patent_app_date] => 2018-12-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20923
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16218353
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/218353 | TREATMENT OF AMD USING AAV2 VARIANT WITH AFLIBERCEPT | Dec 11, 2018 | Abandoned |
Array
(
[id] => 16861637
[patent_doc_number] => 11020359
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-06-01
[patent_title] => Method, compositions and device for nano-enhanced opto-chemical trans-differentiation of cells and tissues
[patent_app_type] => utility
[patent_app_number] => 16/215578
[patent_app_country] => US
[patent_app_date] => 2018-12-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 10
[patent_figures_cnt] => 17
[patent_no_of_words] => 9248
[patent_no_of_claims] => 12
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 52
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16215578
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/215578 | Method, compositions and device for nano-enhanced opto-chemical trans-differentiation of cells and tissues | Dec 9, 2018 | Issued |
Array
(
[id] => 18215207
[patent_doc_number] => 11590120
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-02-28
[patent_title] => Psilocybin compositions
[patent_app_type] => utility
[patent_app_number] => 16/211281
[patent_app_country] => US
[patent_app_date] => 2018-12-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5427
[patent_no_of_claims] => 18
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 22
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16211281
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/211281 | Psilocybin compositions | Dec 5, 2018 | Issued |
Array
(
[id] => 18345171
[patent_doc_number] => 20230133281
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-05-04
[patent_title] => MATERIALS AND METHODS INCLUDING FOR SEX SELECTION
[patent_app_type] => utility
[patent_app_number] => 16/768577
[patent_app_country] => US
[patent_app_date] => 2018-12-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 25746
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16768577
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/768577 | MATERIALS AND METHODS INCLUDING FOR SEX SELECTION | Dec 2, 2018 | Pending |
Array
(
[id] => 16915881
[patent_doc_number] => 20210188973
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-06-24
[patent_title] => Activity Modulator
[patent_app_type] => utility
[patent_app_number] => 16/767979
[patent_app_country] => US
[patent_app_date] => 2018-11-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4505
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -7
[patent_words_short_claim] => 16
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16767979
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/767979 | Activity Modulator | Nov 27, 2018 | Abandoned |
Array
(
[id] => 17770459
[patent_doc_number] => 11402394
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-08-02
[patent_title] => Antibodies to TTR and methods of use
[patent_app_type] => utility
[patent_app_number] => 16/198965
[patent_app_country] => US
[patent_app_date] => 2018-11-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 4
[patent_figures_cnt] => 12
[patent_no_of_words] => 14101
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 63
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16198965
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/198965 | Antibodies to TTR and methods of use | Nov 22, 2018 | Issued |
Array
(
[id] => 18172704
[patent_doc_number] => 11572401
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-02-07
[patent_title] => Genetically encoded calcium indicators and methods of use
[patent_app_type] => utility
[patent_app_number] => 16/198166
[patent_app_country] => US
[patent_app_date] => 2018-11-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5798
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 31
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16198166
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/198166 | Genetically encoded calcium indicators and methods of use | Nov 20, 2018 | Issued |
Array
(
[id] => 16452596
[patent_doc_number] => 20200362022
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-11-19
[patent_title] => METHODS AND COMPOSITIONS FOR THE GENERATION AND USE OF HUMANIZED CONFORMATION-SPECIFIC PHOSPHORYLATED TAU ANTIBODIES
[patent_app_type] => utility
[patent_app_number] => 16/762141
[patent_app_country] => US
[patent_app_date] => 2018-11-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 40290
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -27
[patent_words_short_claim] => 56
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16762141
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/762141 | Methods and compositions for the generation and use of humanized conformation-specific phosphorylated tau antibodies | Nov 7, 2018 | Issued |
Array
(
[id] => 16437115
[patent_doc_number] => 20200354441
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-11-12
[patent_title] => TREATMENT OF DISORDERS
[patent_app_type] => utility
[patent_app_number] => 16/760390
[patent_app_country] => US
[patent_app_date] => 2018-10-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 43978
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -32
[patent_words_short_claim] => 23
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16760390
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/760390 | TREATMENT OF DISORDERS | Oct 29, 2018 | Abandoned |
Array
(
[id] => 14836243
[patent_doc_number] => 20190276522
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-09-12
[patent_title] => ANTIBODIES TO ALPHA-SYNUCLEIN AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 16/170468
[patent_app_country] => US
[patent_app_date] => 2018-10-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 23637
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -26
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16170468
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/170468 | Antibodies to alpha-synuclein and uses thereof | Oct 24, 2018 | Issued |
Array
(
[id] => 16930808
[patent_doc_number] => 20210196697
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-07-01
[patent_title] => COMBINATION THERAPIES FOR TREATING BIPOLAR DISORDER AND ADHD, AND METHODS FOR USING THE SAME
[patent_app_type] => utility
[patent_app_number] => 16/756960
[patent_app_country] => US
[patent_app_date] => 2018-10-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 29893
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -24
[patent_words_short_claim] => 17
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16756960
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/756960 | COMBINATION THERAPIES FOR TREATING BIPOLAR DISORDER AND ADHD, AND METHODS FOR USING THE SAME | Oct 23, 2018 | Abandoned |
Array
(
[id] => 15023449
[patent_doc_number] => 20190322729
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-10-24
[patent_title] => COMPOSITIONS AND METHODS RELATED TO K180 DIMETHYLATED H1.0 PROTEIN
[patent_app_type] => utility
[patent_app_number] => 16/164676
[patent_app_country] => US
[patent_app_date] => 2018-10-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 38422
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16164676
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/164676 | COMPOSITIONS AND METHODS RELATED TO K180 DIMETHYLATED H1.0 PROTEIN | Oct 17, 2018 | Abandoned |